{"id":"https://openalex.org/W4399324649","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.tps1122","title":"An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).","display_name":"An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4399324649","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.tps1122"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.tps1122","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.tps1122","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.tps1122","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditya Bardia","raw_affiliation_strings":["UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA","institution_ids":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058935870","display_name":"Ciara Catherine O'Sullivan","orcid":"https://orcid.org/0000-0001-6069-9800","observed_orcids":["https://orcid.org/0000-0001-6069-9800"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ciara Catherine O'Sullivan","raw_affiliation_strings":["Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000862048","display_name":"Reshma L Mahtani","orcid":"https://orcid.org/0000-0002-7711-8627","observed_orcids":["https://orcid.org/0000-0002-7711-8627"]},"institutions":[{"id":"https://openalex.org/I1292848113","display_name":"Baptist Hospital of Miami","ror":"https://ror.org/000pfrh90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1292848113","https://openalex.org/I4210097785"]},{"id":"https://openalex.org/I4210097785","display_name":"Baptist Health South Florida","ror":"https://ror.org/00v47pv90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210097785"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reshma L. Mahtani","raw_affiliation_strings":["Miami Cancer Institute, Baptist Health South Florida, Miami, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Miami Cancer Institute, Baptist Health South Florida, Miami, FL","institution_ids":["https://openalex.org/I1292848113","https://openalex.org/I4210097785"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070081606","display_name":"Sibel H. Blau","orcid":"https://orcid.org/0000-0002-5249-1521","observed_orcids":["https://orcid.org/0000-0002-5249-1521"]},"institutions":[{"id":"https://openalex.org/I4210149734","display_name":"Northwest Medical Specialties","ror":"https://ror.org/05hr4m393","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210149734"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sibel Blau","raw_affiliation_strings":["NW Medical Specialties, Puyallup, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NW Medical Specialties, Puyallup, WA","institution_ids":["https://openalex.org/I4210149734"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082152250","display_name":"Nihal Abdulla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160761","display_name":"Los Alamitos Medical Center","ror":"https://ror.org/057b7mv80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160761"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nihal E. Abdulla","raw_affiliation_strings":["Cancer and Blood Specialty Clinic (CBSC), Los Alamitos, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Blood Specialty Clinic (CBSC), Los Alamitos, CA","institution_ids":["https://openalex.org/I4210160761"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000796303","display_name":"Azka Ali","orcid":"https://orcid.org/0000-0001-7476-6664","observed_orcids":["https://orcid.org/0000-0001-7476-6664"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Azka Ali","raw_affiliation_strings":["Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083023952","display_name":"Rani Bansal","orcid":"https://orcid.org/0000-0002-1342-4692","observed_orcids":["https://orcid.org/0000-0002-1342-4692"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rani Bansal","raw_affiliation_strings":["Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University, Durham, NC","institution_ids":["https://openalex.org/I170897317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012285730","display_name":"Janelle Marie Meyer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janelle Marie Meyer","raw_affiliation_strings":["Oregon Oncology Specialists, Salem, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oregon Oncology Specialists, Salem, OR","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018355368","display_name":"Mridula Annette George","orcid":"https://orcid.org/0000-0003-2013-4017","observed_orcids":["https://orcid.org/0000-0003-2013-4017"]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mridula Annette George","raw_affiliation_strings":["Rutgers, The State University of New Jersey, New Brunswick, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rutgers, The State University of New Jersey, New Brunswick, NJ","institution_ids":["https://openalex.org/I102322142"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059240684","display_name":"Hyo Sook Han","orcid":"https://orcid.org/0000-0002-0072-0257","observed_orcids":["https://orcid.org/0000-0002-0072-0257"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hyo S. Han","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038208006","display_name":"Timothy Pluard","orcid":"https://orcid.org/0000-0002-3640-3077","observed_orcids":["https://orcid.org/0000-0002-3640-3077"]},"institutions":[{"id":"https://openalex.org/I1339091601","display_name":"Saint Luke's Health System","ror":"https://ror.org/0127qs140","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1339091601"]},{"id":"https://openalex.org/I4210137478","display_name":"Saint Luke's Hospital","ror":"https://ror.org/04k1cm432","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1339091601","https://openalex.org/I4210137478","https://openalex.org/I75421653"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy J. Pluard","raw_affiliation_strings":["Saint Luke's Cancer Specialists, Kansas City, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint Luke's Cancer Specialists, Kansas City, MO","institution_ids":["https://openalex.org/I1339091601","https://openalex.org/I4210137478"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035860475","display_name":"Steven W. Papish","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100668","display_name":"Summit Medical Group (United States)","ror":"https://ror.org/017bzf706","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100668"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven W. Papish","raw_affiliation_strings":["Summit Medical Group, Florham Park, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Summit Medical Group, Florham Park, NJ","institution_ids":["https://openalex.org/I4210100668"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028702168","display_name":"Jason Michael Jones","orcid":"https://orcid.org/0000-0001-6460-8427","observed_orcids":["https://orcid.org/0000-0001-6460-8427"]},"institutions":[{"id":"https://openalex.org/I2799572201","display_name":"Avera Health","ror":"https://ror.org/05nter171","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799572201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Michael Jones","raw_affiliation_strings":["Avera Cancer Institute, Sioux Falls, SD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avera Cancer Institute, Sioux Falls, SD","institution_ids":["https://openalex.org/I2799572201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089141566","display_name":"Yuanxin Rong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuanxin Rong","raw_affiliation_strings":["Eisai Inc., Nutley, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Inc., Nutley, NJ","institution_ids":["https://openalex.org/I4210151718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073137051","display_name":"Guozhi Gao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guozhi Gao","raw_affiliation_strings":["Eisai Inc., Nutley, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Inc., Nutley, NJ","institution_ids":["https://openalex.org/I4210151718"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope S. Rugo","raw_affiliation_strings":["University of California, San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"TPS1122","last_page":"TPS1122"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8330000042915344},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9620000123977661},{"id":"https://openalex.org/keywords/her2-low-breast-cancer","display_name":"HER2-low breast cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9760000109672546},{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.8980000019073486},{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":0.7350000143051147},{"id":"https://openalex.org/keywords/bystander-effect","display_name":"bystander effect","score":0.5839999914169312},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.6589999794960022},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.609000027179718},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.7680000066757202},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.33000001311302185}],"concepts":[{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.8151540756225586},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8109472393989563},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.6436992287635803},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5845403075218201},{"id":"https://openalex.org/C2908728163","wikidata":"https://www.wikidata.org/wiki/Q415271","display_name":"Human Epidermal Growth Factor Receptor 2","level":4,"score":0.562631368637085},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5005106925964355},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4989817142486572},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4774949252605438},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44710877537727356},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.44464200735092163},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4301108717918396},{"id":"https://openalex.org/C3019800554","wikidata":"https://www.wikidata.org/wiki/Q3813242","display_name":"Open label","level":3,"score":0.42165905237197876},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40192919969558716},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35585492849349976},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3550161123275757},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3449246883392334},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3361588716506958},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2513308525085449},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19732508063316345},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.10952720046043396},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.tps1122","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.tps1122","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.tps1122","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4402561305","https://openalex.org/W4410803658","https://openalex.org/W4379283161","https://openalex.org/W2807329126","https://openalex.org/W4411291101","https://openalex.org/W3013966199","https://openalex.org/W2947407350","https://openalex.org/W4399323555","https://openalex.org/W4396587384","https://openalex.org/W7162533330"],"abstract_inverted_index":{"TPS1122":[0],"Background:":[1],"Treatment":[2],"options":[3,44],"for":[4,45,134,163],"patients":[5],"(pts)":[6],"with":[7,14,30,47,69,109,123,149],"unresectable":[8,113,145,164],"or":[9,49,111,114,143,146,165,322],"metastatic":[10,51,115,147,166],"BC":[11,52,116],"have":[12,118,139],"improved":[13],"the":[15,174,179,256,261,266,316,319,329,380,392],"development":[16],"of":[17,63,79,89,105,173,188,202,263,276,282,336,341,350,365,367,383],"novel":[18],"targeted":[19],"therapies":[20],"including":[21,168],"trastuzumab":[22],"deruxtecan":[23],"(T-DXd),":[24],"an":[25,60,98],"ADC":[26,61],"directed":[27],"against":[28],"HER2":[29,68,237],"a":[31,37,64,74,81,229],"cytotoxic":[32],"topoisomerase":[33],"I":[34],"inhibitor":[35],"as":[36,73],"payload.":[38],"Currently,":[39],"there":[40],"are":[41],"limited":[42],"treatment":[43,122,156],"pts":[46,108,137,199,253],"HER2+":[48,110,142],"HER2-low":[50,112],"that":[53,76],"has":[54],"progressed":[55],"on":[56,208,214,223,346,379],"T-DXd.":[57,124,169],"BB-1701":[58,90,106,264,370,372],"is":[59,77,91,398],"consisting":[62],"monoclonal":[65],"antibody":[66],"targeting":[67],"eribulin":[70],"(microtubule":[71],"inhibitor)":[72],"payload":[75],"capable":[78],"exerting":[80],"bystander":[82],"effect.":[83],"A":[84],"first-in-human":[85],"dose-finding":[86],"Study":[87,96,126],"101":[88],"ongoing.":[92],"Here":[93],"we":[94],"describe":[95],"205,":[97],"open":[99],"label,":[100],"multicenter,":[101],"phase":[102],"2":[103],"study":[104,270,358],"in":[107,228,391],"who":[117],"disease":[119,151,292],"progression":[120,285],"after":[121],"Methods:":[125],"205":[127],"(NCT06188559)":[128],"includes":[129,259],"dose-optimization":[130,175,320],"and":[131,183,186,217,220,300,305,339,353,371,385],"dose-expansion":[132,248,330,393],"parts":[133],"BB-1701.":[135,189],"Eligible":[136],"must":[138,157],"histologically":[140],"confirmed":[141],"HER2-low,":[144],"BC,":[148,167],"measurable":[150],"per":[152,312],"RECIST":[153,313],"v1.1.":[154],"Prior":[155],"include":[158,177,274,363],"1\u20133":[159],"prior":[160,243],"chemotherapy-based":[161],"regimens":[162],"The":[170,190,247],"primary":[171,257],"objectives":[172,273,361],"part":[176,249,321,394],"determining":[178],"recommended":[180],"dose":[181],"(RD)":[182],"evaluating":[184,260],"safety":[185],"tolerability":[187],"RD":[191],"will":[192,233,250,309,334,362,388],"be":[193,234,310,389],"assessed":[194,311],"by":[195,236,315,323],"randomly":[196],"assigning":[197],"~50":[198],"into":[200],"1":[201,210,216,225],"3":[203],"dosing":[204],"cohorts":[205],"(1.6":[206],"mg/kg":[207,213,222],"day":[209,224],"Q3W,":[211,219],"0.8":[212],"days":[215],"8":[218],"1.2":[221],"Q3W;":[226],"IV)":[227],"2:2:1":[230],"ratio.":[231],"Randomization":[232],"stratified":[235],"status":[238],"(HER2+":[239],"vs.":[240],"HER2-low)":[241],"documented":[242],"to":[244,302,369],"T-DXd":[245],"treatment.":[246],"enroll":[251],"~85":[252],"at":[254,265],"RD;":[255],"objective":[258],"efficacy":[262,278,375],"RD.":[267],"In":[268,356],"both":[269,357],"parts,":[271,359],"secondary":[272],"assessment":[275],"additional":[277],"measures":[279,376],"(i.e.,":[280,377],"duration":[281],"response":[283,303,368],"[DOR],":[284],"free":[286],"survival":[287,290],"[PFS],":[288],"overall":[289],"[OS],":[291],"control":[293],"rate":[294,298],"[DCR],":[295],"clinical":[296],"benefit":[297],"[CBR],":[299],"time":[301],"[TTR]),":[304],"pharmacokinetics.":[306],"Efficacy":[307],"endpoints":[308],"v1.1":[314],"investigator":[317],"during":[318,328],"Blinded":[324],"Independent":[325],"Central":[326],"Review":[327],"part.":[331],"Safety":[332],"assessments":[333],"consist":[335],"recording,":[337],"monitoring,":[338],"grading":[340],"adverse":[342],"events":[343],"(AEs)":[344],"based":[345],"CTCAE":[347],"v5.0,":[348],"AEs":[349],"special":[351],"interest,":[352],"serious":[354],"AEs.":[355],"exploratory":[360],"evaluation":[364],"biomarkers":[366],"immunogenicity;":[373],"other":[374],"PFS":[378],"next":[381],"line":[382],"therapy)":[384],"population":[386],"pharmacokinetics":[387],"analyzed":[390],"only.":[395],"Pt":[396],"enrollment":[397],"currently":[399],"open.":[400],"Clinical":[401],"trial":[402],"information:":[403],"NCT06188559":[404],".":[405]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-06-05T00:00:00"}